Fundraising Fox
Hydrocision
North Billerica, US · Delaware corporation · 3 known investors
Find your way into Hydrocision
132 people in our graph can introduce you to the Hydrocision team.
Sign up to see every warm intro you have to Hydrocision
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Hydrocision team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
HydroCision develops minimally invasive surgical instruments using proprietary FluidJet technology to selectively remove soft tissue in a precise manner. The company serves surgeons and hospitals across multiple medical specialties seeking improved surgical outcomes.
Founders & leadership
PK
PAUL KOWALSKIHead of Spine, R & D, Business DevelopmentPaul Kowalski is Chief Executive Officer at HydroCision, which develops minimally invasive surgical instruments using FluidJet technology for soft tissue removal. He brings over 20 years of experience in medical device sales, marketing, and business leadership, including roles in startup growth, go-to-market strategy, and FDA regulatory navigation.
RA
RICHARD A. LYTLE, IIIExecutive
TD
THOMAS D. ABERTCFO, Board Secretary/TreasurerExecutive officer at HydroCision with extensive background in financial and operational leadership across life sciences, medical devices, and technology sectors. Has led teams through growth and organizational transformation, bringing experience in commercializing innovative technologies from development to market.
PV
PATRICIA VANBLARCOMExecutive
RL
Rick LytlePresident & Chief Executive OfficerRick Lytle is President and CEO of HydroCision, which develops minimally invasive surgical instruments using FluidJet technology. He has spent over two decades in medical technology and healthcare operations, including executive and general management roles at publicly traded companies, and has served as CEO and board member for multiple private equity and venture-backed healthcare firms.
Board
LZ
LONG ZHANBoard director
BG
ME
MARC E. GOLDBERGBoard director
YX
YU XIAOTONGBoard director
DW
DOUG WALLBoard director
TW
TERRY WALLBoard director
HW
Howard W. DonnellyChairman of the Board
Investors · 3
BioVenturesreportedBelmont
How we know: biospace.com · Not right? Tell us
Newbury Venturesreported
How we know: funding news · Not right? Tell us
Oxford Bioscience Partnersreported
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$5.5M disclosed across 2 rounds · 2017–2024
▶$2.5MraisedApr 2025 · 12 investors · BiotechnologyRule 506(b)
▶$2.5MraisedApr 2025 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- PAUL KOWALSKIExecutive Officer
- DOUG WALLDirector
- TERRY WALLDirector
- LONG ZHANDirector
- BRYAN GRULKEDirector
- HOWARD W. DONNELLYDirector
- RICHARD A. LYTLE, IIIExecutive Officer, Director
- THOMAS D. ABERTExecutive Officer
- MARC E. GOLDBERGDirector
- Offering amount
- $3.9M
- Amount sold
- $2.5M
- Proceeds to insiders
- $100.1K
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedMar 2017 · 10 investors · BiotechnologyRule 506(b)
▶$3MraisedMar 2017 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DOUG WALLDirector
- TERRY WALLDirector
- YU XIAOTONGDirector
- PATRICIA VANBLARCOMExecutive Officer
- PAUL KOWALSKIExecutive Officer
- HOWARD DONNELLYDirector
- MARC GOLDBERGDirector
- Offering amount
- $4M
- Amount sold
- $3M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Hinge HealthHinge Health builds a digital healthcare platform designed to help individuals manage musculoskeletal health and related conditions. The company serves health plans, employers, and individuals seeking alternative healthcare approaches.
DoximityDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
PractoPracto operates an online healthcare platform offering a directory of verified doctors, appointment booking at hospitals and clinics, online consultations across 20+ specialities, subscription health plans, diagnostic test collection, and medicine delivery. It also provides practice management and hospital information management software for clinics and hospitals.
Companies working in the same space as Hydrocision.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Hydrocision do?
- HydroCision develops minimally invasive surgical instruments using proprietary FluidJet technology to selectively remove soft tissue in a precise manner. The company serves surgeons and hospitals across multiple medical specialties seeking improved surgical outcomes.
- Who are Hydrocision's investors?
- Hydrocision's investors include BioVentures, Newbury Ventures, Oxford Bioscience Partners.
- How much funding has Hydrocision raised?
- Hydrocision has disclosed $5.5M raised across 2 rounds.
- Where is Hydrocision headquartered?
- Hydrocision is headquartered in North Billerica, US.